Research ArticleArticle

Cytochrome CYP Sources of N-Alkylprotoporphyrin IX after Administration of Porphyrinogenic Xenobiotics to Rats

Simon G. W. Wong, Eva H. Lin and Gerald S. Marks
Drug Metabolism and Disposition September 1999, 27 (9) 960-965;

Abstract

Cytochrome P-450 (CYP) 3A2 and CYP2C11 are sources of 70 and 30%, respectively, of N-vinylprotoporphyrin IX (N-vinylPP) formation after administration of 3-[(arylthio)ethyl]sydnone (TTMS) to rats. Female rats receiving TTMS were pretreated with dexamethasone, which induces CYP3A1 preferentially to CYP3A2. The resulting 12-fold increase in N-vinylPP formation showed that CYP3A1 was also a source ofN-vinylPP. Phenobarbital (PB) pretreatment, which induces CYP2B1/2 and 3A1/2 in male rats, increasedN-vinylPP formation after TTMS administration. Troleandomycin, a selective CYP3A inhibitor, was unable to decrease TTMS-mediated N-vinylPP formation in PB-treated male rats, indicating that CYP2B1/2 were sources ofN-vinylPP. This conclusion was supported by demonstrating a 15-fold increase in TTMSinducedN-vinylPP formation in female rats after CYP2B1/2 induction with PB pretreatment. Allylispropylacetamide (AIA) inactivates rat CYP2B1/2, 2C6, 2C7, 2C11, and 3A1/2. Troleandomycin was unable to decrease N-AIA protoporphyrin IX adduct (N-AIAPP) formation, showing that CYP3A1/2 were not susceptible to AIA-mediated N-alkylation.N-AIAPP formation in females was approximately 30% of that in males, and thus we attribute 30% of N-AIAPP formation in males to the non-gender-specific isozymes (CYP2C6, 2C7, and/or 2B1/2), whereas approximately 70% originates from CYP2C11. PB treatment in female rats resulted in a 5-fold increase inN-AIAPP formation, showing that CYP2B1/2 were also susceptible to N-alkylation mediated by AIA. 1-Aminobenzotriazole elicited formation of equivalent amounts ofN′N-aryl bridged protoporphyrin IX in male and female rat liver, demonstrating that nonselective mechanism-based inactivation is accompanied by nonselective conversion of the CYP heme moieties to N′N-aryl bridged protoporphyrin IX.

Although the cytochrome CYP (CYP)1 family of drug-metabolizing enzymes maintains a wide catalytic diversity, individual CYP isozymes have demonstrated substrate selectivity, a property that has been attributed to structural differences within the active site. Studies on mechanism-based CYP inactivation, in which the substrate is catalytically activated, leading to the destruction of the CYP enzyme in a suicide-type manner, have helped elucidate the structure-function relationships of the CYP family (De Matteis et al., 1983). Porphyrinogenic xenobiotics (Fig.1, a–c) interfere with heme biosynthesis as a consequence of their mechanism-based inactivation of specific CYP isozymes (for a review, see Marks et al., 1988; Ortiz de Montellano and Correia, 1996). Mechanistically, these compounds can alkylate the CYP heme moiety at one of the four pyrrole nitrogens within the active site, producing a modified heme adduct referred to asN-alkylprotoporphyrin IX (N-alkylPP; Fig.2). Depletion of free heme levels results from a combination of heme N-alkylation, and the potent inhibitory action of certain N-alkylPPs (i.e.,N-ethylPP, and N-vinylPP) on ferrochelatase, the terminal enzyme in heme synthesis, as seen with the metabolism of two prototypical porphyrinogenic agents, 3-[(arylthio)ethyl]sydnone (TTMS; Fig. 1a) and 3,5-diethoxycarbonyl-1,4-dihydro-2,6-dimethyl-4-ethylpyridine (4-ethylDDC, Fig. 1b; Tephly et al., 1979; Ortiz de Montellano et al., 1981a; Marks et al., 1985; McCluskey et al., 1986; Ortiz de Montellano and Grab, 1986; Sutherland et al., 1986). Alternatively, porphyria can be induced through continual heme depletion, where repeated mechanism-based inactivation dissociates the CYP modified heme moiety from an intact, and heme-reconstitutable, apoprotein, as seen with allylisopropylacetamide (AIA; Fig. 1c; Bornheim et al., 1987).

Figure 1
Figure 1

Mechanism-based inactivators of CYP.

a, TTMS; b, 4-ethylDDC; c, AIA; d, ABT. Note that a, b, and c elicit experimental porphyria, however, d does not.

Figure 2
Figure 2

Structure of N-alkylPP (a) and NNAPP (b).

Recognizing that mechanism-based inactivation of CYP isozymes can play a critical role in experimental porphyria, the use of animal models to predict the potential human porphyrinogenicity of a drug is complicated by species differences in CYP isozyme expression. Drug-induced porphyria seen in animals may depend on N-alkylPP formation from a nonhuman isozyme, and these drugs may be unable to elicit porphyrinogenic effects in humans. Thus, to establish adequate animal test models for drug-induced porphyria, knowledge of human and animal CYP isozyme involvement in mechanism-based inactivation is required. Our laboratory has been interested in determining the in vivo CYP isozyme sources of N-alkylPP in rats after the administration of prototypical porphyrinogenic agents (McNamee and Marks, 1996; Wong et al., 1998). Recognizing the limitations in the selectivity of CYP isozyme inhibitors, we have exploited gender differences in CYP isozyme expression in rats to determine the contribution of specific isozymes to N-alkylPP formation.

CYP3A2 has been shown to be a major source of N-vinylPP formation after administration of TTMS to male rats. However, the role of CYP3A1 in N-vinylPP formation was not determined. Dexamethasone (DEX) pretreatment in female rats has been shown to induce CYP3A1 with minimal effects on CYP3A2, in contrast to DEX pretreatment in males where both CYP3A1 and CYP3A2 are elevated (Cooper et al., 1993; Ghosal et al., 1996). Our first objective in this study was to determine whether CYP3A1 was a source of N-vinylPP formation by determining the effect of DEX pretreatment on TTMS-mediated N-vinylPP formation in female rats.

Previously, phenobarbital (PB) induction in male rats elevatedN-vinylPP formation after TTMS administration (McNamee and Marks, 1996), but because the levels of both CYP3A and 2B1/2 are increased by this inducer (Waxman et al., 1985), the relative contributions of these two isozymes was uncertain. PB pretreatment in female rats, however, is more selective for CYP2B1/2 than CYP3A1/2 (Waxman et al., 1985). The second objective in this study was to determine the role of CYP2B1/2 in N-vinylPP formation after administration of TTMS to rats, by determining the effect of 1) troleandomycin (TAO), a selective CYP3A inhibitor, onN-vinylPP formation in PB-treated male rats and 2) PB pretreatment on N-vinylPP formation in female rats.

AIA (Fig. 1c) is another prototypical porphyrinogenic agent that elicits mechanism-based inactivation and experimental porphyria through continual heme depletion (De Matteis et al., 1980; Ortiz de Montellano and Mico, 1981). AIA inactivates rat CYP 2B1, 2C6, 2C7, 2C11, and 3A in vivo (Bornheim et al., 1987) and elicits in vitro NADPH-dependent mechanism-based inactivation of CYP2B1/2 (Ortiz de Montellano and Mico, 1981). Although it is a prerequisite for N-alkylation, mechanism-based inactivation does not always lead toN-alkylPP formation. For example, mechanism-based inactivation can involve CYP apoprotein alkylation or destruction of the heme moiety, rather than N-alkylPP formation. WhereasN-alkylPP formation from AIA has been previously documented, the CYP isozymes, which are important sources of N-alkylPP remain to be elucidated. Therefore, our third objective was to determine the CYP isozyme sources of AIA-protoporphyrin adduct (N-AIAPP, Fig. 2a) formation after AIA administration.

1-Aminobenzotriazole (ABT; Fig. 1d) is a mechanism-based CYP inactivator that elicits a 90% loss in total CYP content and has low isozyme selectivity (Ortiz de Montellano et al., 1981c; Ortiz de Montellano and Mathews, 1981). Inactivation by ABT has been proposed to predominantly proceed through alkylation of the CYP heme moiety with the formation of an N-N-aryl-bridged protoporphyrin IX (NNAPP; Fig. 2b; Ortiz de Montellano and Mathews, 1981). IfN-alkylation is the primary mechanism by which ABT nonselectively inactivates CYP, NNAPP formation should be similar in male and female rats, despite the marked gender differences in CYP isozyme expression. Our final objective in this study was to investigate the hypothesis that ABT-mediated CYP inactivation proceeds through nonselective heme N-alkylation by comparing NNAPP formation in male and female rats after ABT administration.

Materials and Methods

Reagents and Chemicals.

TTMS was obtained from Color Your Enzyme (Bath, Ontario, Canada). AIA was obtained as a gift from Hoffman-La Roche Ltd. (Vaudreuil, Quebec, Canada). Solvents (methanol, dichloromethane, and acetone) were purchased from VWR Canada (Mississauga, Ontario, Canada). Inhibitors (TAO) and inducers (DEX and PB) were purchased from Sigma Chemical Co. (St. Louis, MO.).

Treatment of Animals.

Male Sprague-Dawley rats (200–250 g) were used for inhibitor studies with TAO and the erythromycin N-demethylase (ERND) assay (described below), and male and female rats (150–200 g) were used for the gender studies. All rats were obtained from Charles River Canada, Inc. (St. Constant, Quebec, Canada). All rats received Purina Laboratory Chow (5001) and water ad libitum and were housed under controlled conditions (22°C, 14:10 h light/dark cycle). Animals were allowed a 1-week environmental adjustment period.

Induction Studies.

When appropriate, rats received either DEX or PB, dissolved in 0.5 ml vehicle, i.p. once daily for 4 days. The vehicle for DEX (100 mg/kg) was dimethyl sulfoxide, and the vehicle for PB (80 mg/kg) was deionized water. Control animals received vehicle (0.5 ml) once daily for 4 days.

Inhibitor Studies.

The inhibitor TAO was coadministered with TTMS (111.3 mg/kg) or AIA (100 mg/kg) 24 h after the final dose of inducer, when appropriate. For experiments with TTMS, 450 mg/kg TAO was used; for AIA, 150 mg/kg TAO was used.

Isolation, Purification, and Separation ofN-AlkylPP.

Four hours after administration of porphyrinogenic compounds, in the presence or absence of inhibitor, rats were decapitated and their livers perfused in situ with 100 ml of ice-cold 1.15% potassium chloride solution. Livers were individually weighed and homogenized in ice-cold 5% concentrated H2SO4/methanol (v/v; 100 ml/liver) and stored in the dark at 4°C for 24 h. The resulting mixture containing N-alkylPP dimethyl ester was filtered, diluted with an equal volume of deionized water, and extracted with dichloromethane (2 × 30 ml) in a separatory funnel. After successive washes with 5% sodium bicarbonate (80 ml) and deionized water (2 × 80 ml), the dichloromethane solution was dried over anhydrous sodium sulfate. After removal of the sodium sulfate by filtration, zinc acetate (25 μmol) in methanol (2 ml) was added to form the Zn-N-alkylPP dimethyl ester, and the solution was evaporated to dryness. The residue was dissolved in dichloromethane and applied to an Analtech (Newark, DE) Silica gel G thin-layer chromatography (TLC) plate (2000 μm) and developed in dichloromethane/methanol (13:2) for 60 min. A single green band (Rf = 0.68–0.74) that fluoresced red under long-wavelength UV light was eluted from the plate with acetone and evaporated to dryness. The residue was dissolved in dichloromethane, applied to a second Analtech Silica Gel G TLC plate (1000 μm), and developed in dichloromethane/acetone (5:1) for 45 to 50 min. A green band (Rf = 0.67–0.80) that fluoresced red under long wavelength UV light was eluted with acetone. The electronic absorption spectrum was determined using a Hewlett-Packard 8451A diode array spectrophotometer. The concentrations of the Zn-N-vinylPP dimethyl ester and Zn-N-AIAPP dimethyl ester were estimated using the molar extinction coefficient for Zn-N-methylPP dimethyl ester (ε > 124,000 m−1cm−1 at 432 nm; Ortiz de Montellano et al., 1981b). It was assumed that the molar extinction coefficients of Zn-N-vinylPP and Zn-N-AIAPP dimethyl esters were similar to that of Zn-N-methylPP dimethyl ester. This approximation was necessary because, unlikeN-methylPP dimethyl esters, synthetic samples of the otherN-alkylPP dimethyl esters are not available, and their individual molar extinction coefficients cannot be determined.

Isolation, Purification, and Separation of NNAPP.

Isolation, purification, and separation of NNAPP was performed as described above. After separation of the crude product on the first Analtech silica gel TLC plate (2000 μm), two red-fluorescing bands were obtained: a lower band (Rf = 0.1) and a higher band (Rf = 0.5). The high Rf band has been previously observed (Ortiz de Montellano and Mathews, 1981) but remains uncharacterized. The lower band was eluted from the plate and rechromatographed on a second silica gel Analtech plate (1000 μm). A single red-fluorescing band (Rf = 0.1) was eluted from the plate. The electronic absorption spectrum was determined and shown to be the same as that previously reported for NNAPP by Ortiz de Montellano and Mathews (1981). The concentration of NNAPP was estimated using the molar extinction coefficient for Zn-N-methylPP dimethyl ester (ε > 124,000 m−1cm−1 at 432 nm; Ortiz de Montellano et al., 1981b), because an extinction coefficient for NNAPP is not available.

Determination of Microsomal ERND Activity from the Livers of DEX-Treated Male Rats.

Preparation and storage of hepatic microsomes

Twenty-four hours after the final DEX treatment, rats were sacrificed by decapitation, and their livers were perfused in situ with 150 ml of ice-cold 1.15% (w/v) KCl. Livers were excised, blotted dry, and weighed, and then minced and homogenized in 4 volumes of ice-cold phosphate-buffered KCl (1.15%, w/v, KCl, 10 mM K2HPO4, pH 7.4) using a Potter-Elvehjem apparatus. The homogenate was centrifuged (9000g) for 20 min at 4°C. The supernatant was centrifuged (106,000g) for 60 min at 4°C. The pellet was resuspended in ice-cold phosphate-buffered KCl and was recentrifuged (106,000g) for 60 min at 4°C. The final microsomal pellets were immediately frozen by immersion in liquid nitrogen.

Inactivation of Microsomal CYP.

Microsomal pellets were thawed and resuspended in 17 ml of 0.1 M K2HPO4 buffer (pH 7.4) containing 1.5 mM EDTA to yield a protein concentration of approximately 4 to 6 mg/ml. Two milliliters of the microsomal suspension and 2 ml of 2.0 mM NADPH (dissolved in buffer) were incubated with AIA (10 mM) for 30 min at 37°C in a shaking water bath. The reaction was stopped by cooling on ice, and samples were then centrifuged (106,000g) for 60 min at 4°C. Microsomal pellets were immediately frozen in liquid nitrogen.

Enzyme Assay.

Microsomal pellets were resuspended in 0.1 M K2HPO4 buffer (pH 7.4) to yield a final protein content of 0.8–1.0 mg/ml and were assayed for ERND activity according to the method of Wrighton et al. (1985). Incubations were run at 37°C in the presence of 1.0 mM erythromycin and 1.2 mM NADPH for 10 min and then analyzed for formaldehyde content by the method of Nash et al. (1953). Microsomal protein was assayed by the method of Lowry et al. (1951).

Statistical Analysis.

For the male-female rat gender studies, an unpaired Student’st test was used to determine whether mean values of male and females were significantly different (P < .05). For the inhibitor studies with TAO, an unpaired Student’st test was used to determine whether the mean data of inhibitor-treated rats was significantly different (P < .05) from the control animals receiving no inhibitor. For ERND activity, a randomized design one-way ANOVA with a Newman Keul’s post hoc test was used to determine whether the means were significantly different.

Results and Discussion

Studies with TTMS.

Effect of DEX induction on N-vinylPP formation in female rats

Previously, CYP3A2 and 2C11 have been shown to be the major sources of TTMS-mediated N-vinylPP formation in rats (McNamee and Marks, 1996; Wong et al., 1998); however, the role of CYP3A1 was not determined. Administration of DEX to female rats has been previously shown to induce CYP3A1, in contrast to the effect in males where both CYP3A1 and CYP3A2 are induced (Waxman et al., 1985; Cooper et al., 1993; Ghosal et al., 1996). Therefore, using DEX to induce primarily CYP3A1 in females would allow us to determine whether this isozyme was susceptible to TTMS-mediated N-vinylPP formation. DEX induction (50 mg/kg for 4 days) produced a large (12-fold) increase in N-vinylPP formation (Fig.3a). We conclude that the increasedN-vinylPP formation is due primarily to increased mechanism-based inactivation of CYP3A1 with concomitantN-vinylPP formation and that TTMS elicits mechanism-based inactivation and N-vinylPP formation from both CYP3A1 and CYP3A2.

Figure 3
Figure 3

Effect of pretreatment with DEX or PB on N-vinylPP formation after administration of TTMS.

N-vinylPP formation was determined after pretreatment with DEX (a) or PB (b) to female rats after administration of TTMS. Each bar represents the mean (±S.D.) of determinations from four rats. ***Significantly different (P < .001) from control, as determined by an unpaired Student’s ttest.

Role of CYP2B1/2 in N-vinylPP formation.

Previously, PB pretreatment increased N-vinylPP formation after TTMS administration to male rats (McNamee and Marks, 1996). However, because PB elevates the levels of both CYP2B1/2 and CYP3A1/2 in male rats (Waxman et al., 1985), the relative contributions of these two isozymes to the observed increase in N-vinylPP formation was uncertain. To investigate the role of CYP3A in N-vinylPP formation in PB-induced rats, TAO, a selective inhibitor of CYP3A (Chang et al., 1994) was administered to PB-induced male rats (results not shown). TAO was unable to significantly effect N-vinylPP formation in PB-induced animals, indicating that CYP3A was not an important source of N-vinylPP in PB-induced male rats. This conclusion suggests that the other CYP isozymes elevated in PB-induced rats, namely CYP2B1/2, are likely sources of the increasedN-vinylPP formation. PB pretreatment in female rats is more selective for CYP2B1/2 than CYP3A, compared to its effect in males where CYP2B1/2 and CYP3A are induced (Waxman et al., 1985). Thus, to examine the role of 2B1 in N-vinylPP formation, the effect of PB induction (100 mg/kg for 4 days) on N-vinylPP formation after administration of TTMS to female rats was determined. Figure 3b indicates that PB-induced rats produced a 15.3-fold increase in N-vinylPP formation compared to control rats, supporting the results with TAO, namely that the main PB-inducible isoforms, namely CYP2B1/2, are major sources of N-vinylPP in PB-treated rats.

Studies with AIA.

Effect of AIA on CYP3A activity

Previous studies have indicated that AIA inactivates CYP 2B1, 2C6, 2C7, 2C11, and 3A in vivo (Bornheim et al., 1987), although it was not determined whether this inactivation was NADPH-dependent and therefore likely to be mechanism-based. Other in vitro studies, however, have shown that the PB-inducible isozymes, namely CYP2B1/2, undergo NADPH-dependent mechanism-based inactivation (Ortiz de Montellano and Mico, 1981). Previously, CYP3A was shown to be susceptible to NADPH-dependent inactivation and the major source of N-vinylPP from TTMS (McNamee and Marks, 1996) in untreated and DEX-pretreated rats. Therefore, in the present study, we decided to determine whether AIA elicited similar effects on CYP3A. The effect of AIA on ERND activity, a selective catalytic marker for CYP3A isozymes (Wrighton et al., 1985), was determined in vitro, and the data are summarized in Fig. 4. ERND activity in microsomes receiving NADPH, regardless of the presence of AIA, was significantly lower than activity from microsomes where NADPH was absent. This finding is consistent with a previous report of Riddick et al. (1989), who observed NADPH-dependent decreases in total CYP content in microsomes isolated from DEX-treated rats, due to lipid peroxidation leading to destruction of CYP, despite the inclusion of 1.5 mM EDTA in the incubation medium. For this reason, the effects of mechanism-based inactivators were expressed with respect to the control incubation in the presence of NADPH alone. In the presence of NADPH, AIA significantly decreased ERND activity by 31%. However, in the absence of NADPH, AIA was unable to decrease ERND activity, showing that NADPH is required for CYP inactivation and that this process is likely to be mechanism-based. Thus, as observed with other porphyrinogenic agents such as TTMS and 4-ethylDDC, AIA elicits mechanism-based inactivation of CYP3A.

Figure 4
Figure 4

ERND activity in rat hepatic microsomal preparations from dexamethasone-pretreated rats after in vitro incubation with AIA and/or NADPH.

Each bar represents the mean (±S.D.) of determinations from three rats. Group means with different letters are statistically different (P < .05) from each other.

Effect of CYP3A inhibition on N-AIAPP formation.

During mechanism-based CYP inactivation, one possible outcome is theN-alkylation of the isozyme’s heme moiety, followed by the dissociation of the AIA-porphyrin adduct from the apoprotein. Because AIA elicited mechanism-based inactivation of CYP3A, we decided to investigate the effect of CYP3A inhibition, mediated by TAO, on the production of N-AIAPP), and the data are summarized in Fig.5a. Administration of TAO resulted in a 2.4-fold increase in N-AIAPP formation. This observation was surprising because we anticipated a decrease in N-AIAPP formation if CYP3A was a major source of the N-alkylated heme adducts. The inability of CYP3A inhibition to decreaseN-AIAPP formation indicates that this isozyme is not a source N-AIAPP. Other investigators have provided evidence suggesting that CYP3A is not a likely candidate forN-alkylPP formation. Thus, Bornheim et al. (1987)demonstrated that AIA-mediated decreases in CYP3A activity were not restored after the administration of heme and concluded that this isozyme is inactivated through other destructive mechanisms without dissociation of modified heme-adducts from an intact apoprotein and without N-AIAPP formation. We propose that when TAO inactivates CYP3A, more AIA is available to react with other CYP isozymes that are susceptible to N-alkylation and can formN-AIAPP, resulting in the observed 2.4-fold increase inN-AIAPP formation. In the absence of TAO, a large percentage of AIA can interact with CYP3A without N-AIAPP formation, reducing the amount of AIA available to react with other isozymes that are susceptible to N-alkylation.

Figure 5
Figure 5

N-AIAPP formation after administration of AIA.

a, effect of TAO coadministration with AIA on N-AIAPP formation in male rats. b, N-AIAPP formation in male and female rats after administration of AIA. c, effect of PB pretreatment on N-AIAPP formation in female rats after administration of AIA. Each bar represents the mean (±S.D.) of determinations from four rats.*Significantly different (P < .05); **significantly different (P < .01), as determined by an unpaired Student’s t test.

N-AIAPP formation in male and female rats.

A marked gender difference in rat hepatic N-alkylPP formation has been demonstrated after administration of TTMS and 4-ethylDDC, which is attributable to the contributions of male-specific CYP2C11 (for both TTMS and 4-ethylDDC) and CYP3A2 (TTMS only) toN-alkylation. Figure 5b indicates that, as we previously observed with TTMS and 4-ethylDDC, male rats produced markedly more (3-fold) N-alkylPP than females after AIA administration, and because the TAO study ruled out CYP3A as a source ofN-AIAPP, we attribute this difference to the contribution of CYP2C11 in males. Female rat N-AIAPP production, which was approximately 30% of that in males, must originate from the major CYP isozymes known to be constitutively expressed in females, namely CYP2B1/2, 2C6, and 2C12. Moreover, because the levels of CYP2C6 and 2B1 exist in similar levels in male and female rats (Waxman et al., 1985), the N-AIAPP production in females approximately represents the contributions of these isozymes in male rats. Therefore, in untreated male rats, approximately 30% of N-AIAPP formation originates from CYP2C6 and 2B1, whereas CYP2C11 is the source of the remaining 70%. Our results, indicating that CYP2C11 is the major source of N-AIAPP formation from AIA in male rats, are consistent with previous observations by Bornheim et al. (1987), demonstrating that AIA-mediated destruction of CYP2C11 activity is heme-restorable.

Effect of PB induction on N-AIAPP formation in female rats.

A previous study with AIA has suggested that PB-inducible isozymes, namely CYP2B1/2, are important targets for mechanism-based inactivation (Ortiz de Montellano and Mico, 1981), and if these isozymes are also major sources of N-alkylPP, then induction of CYP2B1/2 with PB should increase N-AIAPP formation. Thus, the effect of PB induction on N-AIAPP formation in female rats was determined and shown in Fig. 5c. PB induction (80 mg/kg for 4 days) resulted in a 5-fold increase in N-AIAPP formation. We conclude that the increased N-AIAPP formation is due to an increase in CYP2B1/2 levels, which has been reported to be 15-fold in female rats and that CYP2B1/2 are highly susceptible to AIA-mediated N-alkylation. This observation is consistent with previous studies indicating that PB-inducible isozymes were susceptible to AIA-mediated mechanism-based inactivation. Furthermore, our results are consistent with evidence demonstrating that AIA-mediated inactivation of CYP2B1/2 activity can be restored by heme administration, suggesting that the primary mechanism of inactivation is heme N-alkylation without destruction of the apoprotein.

Studies with ABT.

NNAPP adduct formation in male and female rats

The final objective of this study was to determine whether ABT elicited nonselective mechanism-based CYP inactivation through nonselective heme N-alkylation and the formation of NNAPP. ABT (100 mg/kg) was administered to male and female rats, and NNAPP was isolated (Fig.6). There was no significant difference in NNAPP formation in male and female rats. Because NNAPP formation was similar in male and female rats despite the gender differences in rat CYP isozyme expression, we conclude that NNAPP formation is the primary mechanism by which ABT elicits nonselective, mechanism-based inactivation.

Figure 6
Figure 6

NNAPP formation in male and female rats after administration of ABT.

Each bar represents the mean (±S.D.) of determinations from four rats.

Conclusions

In summary, the main male rat isozyme targeted for mechanism-based inactivation and N-alkylPP formation by AIA is CYP2C11 (approximately 70%), with the remaining 30% originating from other important constitutively expressed isozymes, namely CYP2C6 and CYP2B1/2. The conclusion that CYP2C11 is susceptible toN-alkylation has been previous reported by our laboratory. CYP2C11 was a major source of N-ethylPP formation (78%) after administration of 4-ethylDDC and also a source ofN-vinylPP formation from TTMS (32%; Wong et al., 1998). In contrast, whereas CYP3A is susceptible to mechanism-based inactivation by all three drugs, only TTMS elicits N-alkylation. Therefore, the unique mechanism by which TTMS interacts with CYP3A must facilitate N-vinylPP formation, whereas interactions with 4-ethylDDC and AIA promote alternate pathways to inactivation, perhaps leading to destruction of the heme and/or apoprotein.

The consistently lower N-alkylPP formation in female rats compared to males after the administration of TTMS, 4-ethylDDC, and AIA suggests that the female specific CYP2C12 is not as susceptible toN-alkylPP formation as the male-specific CYP2C11. Therefore, there must be distinct structural properties of CYP2C11 that facilitateN-alkylPP formation, whereas CYP2C12 is not susceptible to this form of mechanism-based inactivation despite the fact that the CYP2C family is closely related and has considerable immunochemical cross-reactivity (Bandiera et al., 1985). Furthermore, the observed rat gender differences in N-alkylPP formation with all three compounds suggests that if rats are used for screening potentially porphyrinogenic drugs, studies in both male and female rats are required.

If hepatic CYP isozymes targeted for mechanism-based inactivation andN-alkylPP formation by TTMS, 4-ethylDDC, and AIA in the rat are similarly targeted in human liver, it would be reasonable to deduce that these xenobiotics would also exhibit porphyrinogenic properties in humans. In previous studies, we found that 4-ethylDDC and TTMS caused mechanism-based inactivation of cDNA expressed human CYP1A1, 1A2, and 3A4, whereas only 4-ethylDDC was able to elicit mechanism-based inactivation of CYP2C9 (McNamee et al., 1997). Although CYP1A1 and CYP1A2 undergo TTMS-mediated mechanism-based inactivation in rat liver, induction studies with β-naphthoflavone showed that neither of these isozymes are quantitatively important sources of N-vinylPP in the rat (McNamee and Marks, 1996). Considering this information and our previous finding that CYP3A2 is quantitatively the major source ofN-vinylPP in rats, the most likely source ofN-vinylPP formation in humans is CYP3A4. On the other hand, 4-ethylDDC causes mechanism-based inactivation and N-alkylPP formation from rat CYP2C11, thus implicating a role for human CYP2C9 as a source of N-alkylPP. Our future studies will therefore be directed to determining whether N-alkylPPs are formed during the interaction of TTMS and 4-ethylDDC with human CYP3A4 and CYP2C9, respectively. AIA causes mechanism-based inactivation of several rat CYP isozymes, and it was therefore surprising to find that it did not inactivate any of the major human hepatic isozymes (McNamee et al., 1997). Our future studies will therefore be directed to determining whether AIA elicits mechanism-based inactivation of one or several of the minor human hepatic CYP isozymes and if it does, to determining whether N-alkylPP formation accompanies this inactivation.

Footnotes

  • Send reprint requests to: Gerald S. Marks, Ph.D., Department of Pharmacology and Toxicology, Faculty of Health Sciences, Queen’s University, Kingston, Ontario, Canada K7L 3N6. E-mail:gsm{at}post.queensu.ca

  • This research was supported by the Medical Research Council of Canada.

  • Abbreviations used are::
    N-alkylPP
    N-alkylprotoporphyrin IX
    N-vinylPP
    N-vinylprotoporphyrin IX
    N-ethylPP
    N-ethylprotoporphyrin IX
    4-ethylDDC
    3,5-diethoxycarbonyl-1,4-dihydro-2,6-dimethyl-4-ethylpyridine
    TTMS
    3-[(arylthio)ethyl]sydnone
    CYP
    cytochrome P-450
    PB
    phenobarbital
    DEX
    dexamethasone
    TAO
    troleandomycin
    ABT
    1-aminobenzotriazole
    AIA
    allylisopropylacetamide
    N-AIAPP
    N-allyisopropylacetamide protoporphyrin IX (adduct)
    NNAPP
    N′N-aryl bridged protoporphyrin IX
    ERND
    erythromycin N-demethylase
    • Received December 21, 1998.
    • Accepted April 30, 1999.

References

  1. ↵
    1. Bandiera S,
    2. Ryan DE,
    3. Levin W,
    4. Thomas PE
    (1985) Evidence for a family of four immunochemically related isozymes of cytochrome P-450 purified from untreated rats. Arch Biochem Biophys 240:478–482.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Bornheim LM,
    2. Underwood MC,
    3. Caldera P,
    4. Rettie AE,
    5. Trager WF,
    6. Wrighton SA,
    7. Correia MA
    (1987) Inactivation of multiple hepatic cytochrome P-450 isozymes in rats by allylisopropylacetamide: Mechanistic implications. Mol Pharmacol 32:299–308.
    OpenUrlAbstract
  3. ↵
    1. Chang TK,
    2. Gonzalez FJ,
    3. Waxman DJ
    (1994) Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437–442.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Cooper KO,
    2. Reik LM,
    3. Jayyosi Z,
    4. Bandiera S,
    5. Kelley M,
    6. Ryan DE,
    7. Daniel R,
    8. McCluskey SA,
    9. Levin W,
    10. Thomas PE
    (1993) Regulation of two members of the steroid-inducible cytochrome P450 subfamily (3A) in rats. Arch Biochem Biophys 301:345–354.
    OpenUrlCrossRefPubMed
  5. ↵
    1. De Matteis F,
    2. Gibbs AH,
    3. Cantoni L,
    4. Francis J
    (1980) Substrate-dependent irreversible inactivation of cytochrome P-450: Conversion of its haem moiety into modified porphyrins. Ciba Found Symp 76:119–139.
    OpenUrlPubMed
  6. ↵
    1. De Matteis F,
    2. Gibbs AH,
    3. Hollands C
    (1983) N-alkylation of the haem moiety of cytochrome P-450 caused by substituted dihydropyridines. Preferential attack of different pyrrole nitrogen atoms after induction of various cytochrome P-450 isoenzymes. Biochem J 211:455–461.
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Ghosal A,
    2. Satoh H,
    3. Thomas PE,
    4. Bush E,
    5. Moore D
    (1996) Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cDNA-expressed human cytochrome P450. Drug Metab Dispos 24:940–947.
    OpenUrlAbstract
  8. ↵
    1. Lowry OH,
    2. Rosebrough NJ,
    3. Farr AL,
    4. Randall RJ
    (1951) Protein measurement with Folin phenol reagent. J Biol Chem 193:265–275.
    OpenUrlFREE Full Text
  9. ↵
    1. Marks GS,
    2. Allen DT,
    3. Johnston CT,
    4. Sutherland EP,
    5. Nakatsu K,
    6. Whitney RA
    (1985) Suicidal destruction of cytochrome P-450 and reduction of ferrochelatase activity by 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6- trimethylpyridine and its analogues in chick embryo liver cells. Mol Pharmacol 27:459–465.
    OpenUrlAbstract
  10. ↵
    1. Marks GS,
    2. McCluskey SA,
    3. Mackie JE,
    4. Riddick DS,
    5. James CA
    (1988) Disruption of hepatic heme biosynthesis after interaction of xenobiotics with cytochrome P-450 [Review] [40 refs]. FASEB J 2:2774–2783.
    OpenUrlAbstract
  11. ↵
    1. McCluskey SA,
    2. Marks GS,
    3. Sutherland EP,
    4. Jacobsen N,
    5. Ortiz de Montellano PR
    (1986) Ferrochelatase-inhibitory activity and N-alkylprotoporphyrin formation with analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine (DDC) containing extended 4-alkyl groups: Implications for the active site of ferrochelatase. Mol Pharmacol 30:352–357.
    OpenUrlAbstract
  12. ↵
    1. McNamee JP,
    2. Marks GS
    (1996) Cytochrome P4503A is the major source of N-vinylprotoporphyrin IX formation after administration of 3-[2-(2,4,6-trimethylphenyl)thioethyl]-4-methylsydnone to untreated and dexamethasone-pretreated rats. Drug Metab Dispos 24:872–878.
    OpenUrlAbstract
  13. ↵
    1. McNamee JP,
    2. Jurima-Romet M,
    3. Kobus SM,
    4. Marks GS
    (1997) cDNA-expressed human cytochrome P450 isozymes. Inactivation by porphyrinogenic xenobiotics. Drug Metab Dispos 25:437–441.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Nash T
    (1953) The colorimetric estimation of formaldehyde by means of the Hantzsch reaction. Biochem J 55:416–421.
    OpenUrlFREE Full Text
  15. ↵
    1. Ortiz de Montellano PR,
    2. Beilan HS,
    3. Kunze KL
    (1981a) N-Alkylprotoporphyrin IX formation in 3,5-dicarbethoxy-1,4- dihydrocollidine-treated rats. Transfer of the alkyl group from the substrate to the porphyrin. J Biol Chem 256:6708–6713.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Ortiz de Montellano PR,
    2. Beilan HS,
    3. Kunze KL
    (1981b) N-Methylprotoporphyrin IX: Chemical synthesis and identification as the green pigment produced by 3,5-diethoxycarbonyl-1,4- dihydrocollidine treatment. Proc Nat Acad Sci USA 78:1490–1494.
    OpenUrlAbstract/FREE Full Text
  17. ↵
    1. Ortiz de Montellano PR,
    2. Mathews JM
    (1981) Autocatalytic alkylation of the cytochrome P-450 prosthetic haem group by 1-aminobenzotriazole. Isolation of an N′N-bridged benzyne-protoporphyrin IX adduct. Biochem J 195:761–764.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Ortiz de Montellano PR,
    2. Mico BA
    (1981) Destruction of cytochrome P-450 by allylisopropylacetamide is a suicidal process. Arch Biochem Biophys 206:43–50.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Ortiz de Montellano PR,
    2. Mico BA,
    3. Mathews JM,
    4. Kunze KL,
    5. Miwa GT,
    6. Lu AY
    (1981c) Selective inactivation of cytochrome P-450 isozymes by suicide substrates. Arch Biochem Biophys 210:717–728.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Ortiz de Montellano PR,
    2. Grab LA
    (1986) Inactivation of cytochrome P-450 during catalytic oxidation of a 3-[(arylthio)ethyl]sydnone: N-vinyl heme formation via insertion into the Fe-N bond. J Am Chem Soc 108:5584–5589.
    OpenUrlCrossRef
  21. ↵
    1. Ortiz de Montellano PR,
    2. Correia MA
    (1996) Inhibition of cytochrome P450 enzymes. Cytochrome P450: Structure, Mechanism, and Biochemistry (Plenum Press, New York), pp 305–364.
  22. ↵
    1. Riddick DS,
    2. Park SS,
    3. Gelboin HV,
    4. Marks GS
    (1989) Effects of a series of 4-alkyl analogues of 3,5-diethoxycarbonyl-1,4-dihydro-2,4,6-trimethylpyridine on the major inducible cytochrome P-450 isozymes of rat liver. Mol Pharmacol 35:626–634.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Sutherland EP,
    2. Marks GS,
    3. Grab LA,
    4. Ortiz de Montellano PR
    (1986) Porphyrinogenic activity and ferrochelatase-inhibitory activity of sydnones in chick embryo liver cells. FEBS Lett 197:17–20.
    OpenUrlCrossRefPubMed
  24. ↵
    1. Tephly TR,
    2. Gibbs AH,
    3. De Matteis F
    (1979) Studies on the mechanism of experimental porphyria produced by 3,5-diethoxycarbonyl-1,4-dihydrocollidine. Role of a porphyrin-like inhibitor of protohaem ferro-lyase. Biochem J 180:241–244.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Waxman DJ,
    2. Dannan GA,
    3. Guengerich FP
    (1985) Regulation of rat hepatic cytochrome P-450: Age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. Biochemistry 24:4409–4417.
    OpenUrlCrossRefPubMed
  26. ↵
    1. Wong SG,
    2. Kobus SM,
    3. McNamee JP,
    4. Marks GS
    (1998) Gender differences in N-alkyl protoporphyrin IX production in rats after the administration of porphyrinogenic xenobiotics. Drug Metab Dispos 26:739–744.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Wrighton SA,
    2. Schuetz EG,
    3. Watkins PB,
    4. Maurel P,
    5. Barwick J,
    6. Bailey BS,
    7. Hartle HT,
    8. Young B,
    9. Guzelian P
    (1985) Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat. Mol Pharmacol 28:312–321.
    OpenUrlAbstract
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleArticle

Cytochrome CYP Sources of N-Alkylprotoporphyrin IX after Administration of Porphyrinogenic Xenobiotics to Rats

Simon G. W. Wong, Eva H. Lin and Gerald S. Marks
Drug Metabolism and Disposition September 1, 1999, 27 (9) 960-965;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section